Mutations in KRAS are the most common oncogenic driver mutations in human cancers. The KRAS G12C mutation is one of the most prevalent KRAS mutations, present in approximately 12% of non-small cell lung cancer, 4% of colorectal cancer, and up to 4% of other cancer types. The recent discovery and development of covalent KRAS G12C inhibitors provides an opportunity to inhibit what has historically been considered to be an “undruggable” target.<br/><br/>GDC-6036 is an orally bioavailable, highly potent and selective KRAS G12C inhibitor. GDC-6036 demonstrates greater potency and selectivity compared with other KRAS G12C inhibitors <i>in vitro</i>, and complete tumor growth inhibition in multiple KRAS G12C-positive cell lines and in xenograft mouse models. We will present the program that led to the discovery and optimization of GDC-6036, which is currently in clinical development.

Discovery of GDC-6036, a clinical stage treatment for KRAS G12C-positive cancers

Fall 2022 abstracts, posters, and presentations will launch in mid-September.

ACS Fall 2022

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.